Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Mkt Cap
Market Capitalization
₹700Cr
Rev Gr TTM
Revenue Growth TTM
-50.16%
Peer Comparison
Compare up to 10 companies side by side across valuation, profitability, and growth.

SADHNANIQ
VS
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|
|
Growth YoY Revenue Growth YoY% | 20.9 | 43.6 | 15.0 | 41.3 | 34.0 | -8.4 | 2.1 | -15.8 | -23.4 | -22.2 | -93.7 | -73.7 |
| 38 | 32 | 29 | 33 | 55 | 26 | 35 | 26 | 36 | 26 | 20 | 25 |
Operating Profit Operating ProfitCr |
| 20.1 | 19.9 | 29.8 | 25.9 | 14.4 | 26.6 | 19.3 | 30.3 | 26.7 | 6.9 | -628.9 | -155.6 |
Other Income Other IncomeCr | 0 | 1 | 0 | 1 | 2 | 0 | 1 | 0 | 0 | 4 | 0 | 1 |
Interest Expense Interest ExpenseCr | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 4 | 4 | 5 | 7 |
Depreciation DepreciationCr | 3 | 4 | 4 | 4 | 3 | 4 | 4 | 3 | 4 | 5 | 4 | 4 |
| 3 | 0 | 4 | 4 | 4 | 2 | 1 | 4 | 5 | -2 | -26 | -25 |
| 1 | 0 | 2 | 3 | 4 | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
|
Growth YoY PAT Growth YoY% | 175.0 | -94.1 | 794.6 | 24.0 | -70.5 | 933.3 | -89.9 | 177.4 | 688.5 | -441.9 | -9,926.9 | -1,074.4 |
| 3.6 | 0.1 | 6.1 | 2.1 | 0.8 | 1.7 | 0.6 | 7.0 | 8.3 | -7.5 | -946.3 | -257.6 |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.2 | -0.2 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|
|
| 50.2 | -25.6 | 54.0 | 106.6 | 134.3 | -60.3 | -2.8 | 27.8 | 8.8 | 32.6 | -12.9 | -45.6 |
| 52 | 34 | 47 | 79 | 147 | 77 | 80 | 117 | 122 | 149 | 123 | 107 |
Operating Profit Operating ProfitCr |
| -7.6 | 5.4 | 15.0 | 30.6 | 45.1 | 27.4 | 22.7 | 11.1 | 14.8 | 21.6 | 25.6 | -18.9 |
Other Income Other IncomeCr | 14 | 0 | 0 | 0 | 1 | 2 | 5 | 5 | 2 | 4 | 2 | 5 |
Interest Expense Interest ExpenseCr | 5 | 5 | 6 | 5 | 12 | 3 | 3 | 5 | 10 | 17 | 18 | 20 |
Depreciation DepreciationCr | 2 | 2 | 2 | 2 | 3 | 6 | 6 | 6 | 8 | 15 | 15 | 16 |
| 3 | -5 | 1 | 28 | 107 | 22 | 19 | 9 | 6 | 13 | 12 | -48 |
| -1 | 0 | 0 | -3 | 31 | 8 | 3 | 3 | 2 | 9 | 4 | 1 |
|
| 685.9 | -224.8 | 110.3 | 6,019.5 | 143.9 | -80.7 | 8.7 | -60.9 | -48.9 | 28.4 | 85.2 | -744.5 |
| 8.2 | -13.8 | 0.9 | 27.3 | 28.4 | 13.8 | 15.4 | 4.7 | 2.2 | 2.1 | 4.6 | -54.1 |
| 0.1 | 0.0 | 0.0 | 0.3 | 0.7 | 0.0 | 0.1 | 0.1 | 0.0 | 0.0 | 0.1 | -0.4 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|
Equity Capital Equity CapitalCr | 9 | 9 | 9 | 9 | 9 | 9 | 14 | 20 | 20 | 25 | 33 | 33 |
| -7 | -12 | 1 | 37 | 96 | 107 | 116 | 116 | 206 | 202 | 248 | 220 |
Current Liabilities Current LiabilitiesCr | 52 | 59 | 52 | 84 | 64 | 86 | 138 | 178 | 128 | 158 | 198 | 174 |
Non Current Liabilities Non Current LiabilitiesCr | 2 | 2 | 20 | 9 | 7 | 14 | 36 | 48 | 72 | 147 | 158 | 189 |
Total Liabilities Total LiabilitiesCr |
Current Assets Current AssetsCr | 24 | 29 | 34 | 59 | 96 | 112 | 183 | 219 | 224 | 265 | 275 | 262 |
Non Current Assets Non Current AssetsCr | 41 | 39 | 49 | 81 | 81 | 104 | 122 | 167 | 202 | 267 | 362 | 354 |
Total Assets Total AssetsCr |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Operating Cash Flow Operating Cash FlowCr | 9 | -1 | 9 | 35 | 53 | -17 | 1 | -5 | -38 | -3 | 54 |
Investing Cash Flow Investing Cash FlowCr | 0 | 0 | -1 | -6 | -25 | -22 | -23 | -39 | -53 | -65 | -89 |
Financing Cash Flow Financing Cash FlowCr | -9 | 2 | -25 | -13 | -23 | 30 | 30 | 46 | 72 | 42 | 25 |
|
Free Cash Flow Free Cash FlowCr | 9 | -1 | 9 | 35 | 53 | -17 | -7 | -43 | -86 | -69 | -39 |
| 227.2 | 18.6 | 1,782.6 | 112.5 | 69.5 | -114.2 | 4.2 | -75.5 | -1,189.8 | -66.7 | 716.1 |
CFO To EBITDA CFO To EBITDA% | -246.4 | -47.6 | 109.7 | 100.5 | 43.8 | -57.7 | 2.8 | -32.2 | -178.2 | -6.6 | 127.8 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Valuation Ratios Valuation Ratios |
Market Cap Market CapitalizationCr | 12 | 16 | 39 | 204 | 618 | 209 | 358 | 2,580 | 2,314 | 1,544 | 557 |
Price To Earnings Price To Earnings | 3.1 | 0.0 | 76.5 | 6.5 | 8.2 | 71.5 | 22.5 | 412.2 | 715.6 | 367.6 | 73.5 |
Price To Sales Price To Sales | 0.3 | 0.4 | 0.7 | 1.8 | 2.3 | 2.0 | 3.5 | 19.6 | 16.1 | 8.1 | 3.4 |
Price To Book Price To Book | 5.1 | -6.7 | 3.7 | 4.4 | 5.9 | 9.0 | 3.0 | 20.4 | 10.7 | 7.1 | 2.0 |
| -10.6 | 25.2 | 8.9 | 6.0 | 5.1 | 8.8 | 18.4 | 183.9 | 115.2 | 43.1 | 18.8 |
Profitability Ratios Profitability Ratios |
| 30.2 | 47.4 | 51.8 | 61.9 | 74.2 | 70.3 | 60.8 | 43.9 | 51.1 | 55.5 | 62.2 |
| -7.6 | 5.4 | 15.0 | 30.6 | 45.1 | 27.4 | 22.7 | 11.1 | 14.8 | 21.6 | 25.6 |
| 8.2 | -13.8 | 0.9 | 27.3 | 28.4 | 13.8 | 15.4 | 4.7 | 2.2 | 2.1 | 4.6 |
| 27.6 | 0.5 | 14.8 | 54.6 | 105.6 | 15.5 | 10.4 | 5.4 | 4.2 | 6.6 | 5.5 |
| 165.3 | 207.7 | 4.9 | 67.8 | 72.1 | 12.6 | 12.3 | 4.6 | 1.4 | 1.8 | 2.7 |
| 6.0 | -7.2 | 0.6 | 22.3 | 42.9 | 6.8 | 5.2 | 1.6 | 0.8 | 0.8 | 1.2 |
Operational Ratios Operational Ratios |
Solvency Ratios Solvency Ratios |
Liquidity Ratios Liquidity Ratios |
### **Overview**
Sadhana Nitro Chem Ltd. (SNCL), established in 1973 and based in Roha, Maharashtra, is a leading Indian manufacturer of intermediate specialty chemicals, heavy organic chemicals, and performance chemicals. With over 50 years of experience, SNCL operates a 22-acre manufacturing facility and serves a global clientele of multinational corporations. The company is a two-time government-recognized **Golden Export House (2-Star)**, with approximately **80% of its sales exports**, supplying to advanced markets in Europe, North America, Japan, South Korea, and Southeast Asia.
Publicly listed on the **BSE (506642)** and **NSE (SADHNANIQ)**, SNCL is celebrating its 50th anniversary as a listed entity in 2024 and continues to advance its position as a key player in India’s growing chemical manufacturing ecosystem, driven by government initiatives like **Aatmanirbhar Bharat** and the **Production Linked Incentive (PLI) scheme**.
---
### **Key Developments & Strategic Advancements (Recent Period: Sep 2025)**
#### **1. Production Enhancement & Technology Upgrades**
- **PAP (Para-Amino Phenol):**
- Transitioned to a **fully continuous synthesis and separation process**, significantly improving production quality, output consistency, and plant capacity.
- Achieved **premium quality grade for PAP** exceeding global benchmarks (including Chinese competitors), approved by leading clients in Europe, Japan, and Turkey.
- Currently operating at a production run rate of **3,000 TPA**, progressing toward a **36,000 TPA PLI target**.
- Utilizes a **rare hydrogen-based catalytic reduction of nitrobenzene**—a clean chemistry process certified by ICT (formerly UDCT), producing **zero liquid effluent** and co-producing aniline oil and ammonium sulphate.
- **Investment in PAP Project:**
- Over **₹100 crores invested** in R&D, plant infrastructure, machinery, and process development, laying a scalable foundation for future expansion.
#### **2. Expansion in ODB2 Capacity & Market Leadership**
- **ODB2 (Thermal Paper Colour Former):**
- Increased production capacity from **550 TPA to 2,200 TPA**, making SNCL the **largest and lowest-cost global producer** of ODB2.
- **50% of expanded capacity** is already operational, enabling volume-driven competitiveness despite aggressive Chinese pricing.
- **Backward integration** from Nitrobenzene (NB) → m-Aminophenol (MAP) → Keto Acid → ODB2 ensures **full in-house control** over the value chain, eliminating import dependency.
- In 2024, began **in-house manufacturing of a critical raw material**, completing full vertical integration—**SNCL is now the world’s only fully integrated ODB2 manufacturer**.
- Has secured **approvals from all major global paper manufacturers**, reinforcing its role as a preferred alternative to Chinese supply.
#### **3. Diversification into Pharmaceuticals & Advanced Materials**
- **Pharmaceutical Expansion:**
- Leveraging high-purity PAP to enter the **pharmaceutical formulation space**, including **paracetamol production**, aligning with India’s growing role as a global API and drug manufacturer.
- PAP serves as a core intermediate in over-the-counter and prescription pharmaceuticals, with potential for further downstream product development.
- **Legacy Product Innovation:**
- **m-Aminophenol (MAP)** is being co-developed with customers for **next-generation applications** in aerospace, advanced resins, and military-grade materials, unlocking new revenue streams.
#### **4. Export Market Positioning & "China +1" Opportunity**
- **Exports** contributed **28.28% of total revenue** in FY2025 (down from 37.17% in FY2024 due to Chinese dumping), with export turnover declining YoY from ₹7,170 lakhs to ₹3,845 lakhs.
- Despite current headwinds, SNCL maintains a **geographically diversified export footprint**, shipping to **15+ countries** including USA, Germany, UK, Japan, South Korea, Netherlands, Thailand, and UAE.
- Well-positioned to benefit from the **"China +1" sourcing trend**, with growing demand from Western buyers seeking resilient, non-China supply chains.
- Ongoing exploration of **new export corridors in Africa, Southeast Asia, and Europe** to further diversify markets.
#### **5. Technology & Digital Transformation**
- **IoT Integration:**
- Actively implementing **Internet of Things (IoT)** across manufacturing units for:
- Real-time equipment monitoring
- Predictive maintenance
- Automated control systems
- Aims to improve **operational efficiency**, reduce **downtime**, and enable **data-driven decision-making**.
- IoT data will be integrated with **ERP systems** for seamless workflow and process optimization.
- Internal team strengthened to support **ERP rollout and IoT implementation**.
#### **6. Sustainability & Green Initiatives**
- **Green Chemistry & Zero Effluent Goal:**
- PAP manufacturing process is **zero-effluent**; all water is recycled.
- Aiming for **zero effluent discharge across all product lines** within 12–18 months.
- **Green Hydrogen Project:**
- Establishing a **15–20 MW green hydrogen facility** to support sustainable energy transition.
- Expected to lower production costs and improve energy security via **backward integration into green energy**.
- Exploring **carbon capture and utilization (CCU)** and **sustainable fuel switching** to enhance ESG credentials.
- **Solar Energy Adoption:**
- Incorporating solar power into operations to reduce carbon footprint and operational costs.
- Evaluating **government-backed green energy subsidies** to support sustainability investments.
---
### **Operational & Financial Highlights**
- **Workforce:** 248 employees
- **Manufacturing Site:** 22-acre facility in Roha (17 acres MIDC land)
- **Product Portfolio:** 12 specialty chemicals, including:
- **PAP**, **ODB2**, **PFD201** (thermal paper developers)
- **m-Aminophenol**, **Nitrobenzene**, **Aniline Oil**, **DEAP**, **Metanilic Acid**, **3,3-Diaminodiphenyl Sulfone** (aerospace resins)
- **Global Clients:** L’Oréal, Bayer Crop Science, Huntsman, Teijin, Mitsui, Mitsubishi Paper
- **Exports:** Key markets include EU, USA, Japan, Korea; 80% of sales exported
- **R&D Capability:** Government-recognized R&D lab; focuses on **patent-pending green processes** and cost-efficient innovations